Premium
Overview of the benefits and potential issues of the nonavalent HPV vaccine
Author(s) -
Mariani Luciano,
Preti Mario,
Cristoforoni Paolo,
Stigliano Carlo M.,
Perino Antonio
Publication year - 2017
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12075
Subject(s) - medicine , hpv vaccines , hpv infection , cervical cancer , oncology , human papillomavirus , vaccination , gynecology , virology , cancer
HPV ‐related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9v HPV ), covering nine genotypes ( HPV 6, HPV 11, HPV 16, HPV 18, HPV 31, HPV 33, HPV 45, HPV 52, and HPV 58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9v HPV vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9v HPV or the quadrivalent HPV (4v HPV ) vaccine. The 9v HPV vaccine was shown to have potential benefits as compared with 4v HPV , increasing the overall estimated rate of prevention to 90% for cervical cancer and up to 80% for precancerous cervical lesions. For all other HPV ‐related pre‐invasive and invasive lesions, 9v HPV showed potentially greater disease reduction, depending on the anatomic region examined. Thus, the 9v HPV vaccine shows clinical potential for the prevention of HPV ‐related diseases in both sexes. Future adoption of 9v HPV will depend on factors including market price, cost‐effectiveness data, use of a two‐dose schedule, and safety and efficacy monitoring in real‐life programs.